A story reported out by Reuters News Agency yesterday shows very promising results in the study of one of the leading COVID-19 vaccine candidates, AllOTSEGO’s COVID columnist, Dr. Richard Sternberg, reports today.
The vaccine being developed by Oxford University and British Drug maker AstraZenica shows that it produces an immune response, i.e., development of antibodies to the virus, in both the young and the old. This is seen as a very favorable breakthrough in the development of vaccines.
Additionally, it has a low reactogenicity (side effects) in older adults.
Further trials are expected to begin very soon and if they show continued success the British Health Secretary expects roll out early in 2021 and does not rule out beginning general distribution before the end of 2020.